Every 10-Q that Charles River Laboratories International, Inc. (CRL) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow CRL and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CRL filings page.
Charles River Laboratories (CRL) reported Q3 2025 results. Total revenue was $1,004,852,000, slightly below last year’s $1,009,763,000. Service revenue decreased to $808,042,000, while product revenue rose to $196,810,000. Operating income increased to $133,799,000, but higher tax expense and unfavorable other income led to net income attributable to CRL of $54,422,000 versus $69,657,000 a year ago. Diluted EPS was $1.10 compared with $1.33.
By segment, Q3 revenue was: DSA $600,685,000; RMS $213,474,000; and Manufacturing $190,693,000. Operating income improved in RMS and was roughly flat in Manufacturing, while DSA softened slightly. The company changed useful lives for certain assets, reducing depreciation and increasing EPS by about $0.07 in the quarter and $0.21 year‑to‑date.
Year to date, revenue was $3,021,155,000 with diluted EPS of $2.65. Operating cash flow reached $590,126,000, funding $130,202,000 of capex and $360,577,000 of share repurchases. CRL repurchased 2.1 million shares for $350,000,000 and approved a new $1.0 billion authorization on October 29, 2025.